#United States #New York #Levi & Korsinsky #Securities Fraud #Corcept Therapeutics

Levi & Korsinsky Files Class Action on Behalf of Corcept Therapeutics Shareholders

On March 25, 2026, Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, announced the initiation of a class action lawsuit aimed at protecting the interests of shareholders in Corcept Therapeutics Incorporated (NASDAQ: CORT). The lawsuit has been filed in response to alleged securities fraud that took place between October 31, 2024, and December 30, 2025.

Background of the Case

The class action lawsuit arises from accusations that Corcept Therapeutics engaged in deceptive practices that misled investors regarding the status of their relacorilant drug candidate, designed to treat conditions associated with hypercortisolism. The firm is actively seeking to represent investors who incurred losses during the defined period, emphasizing that they may have been adversely affected by these alleged misrepresentations.

According to court documents, the complaint suggests that Corcept’s statements could be materially false or misleading. Specifically, the firm indicates that the FDA had raised significant concerns regarding the company's approach to assessing relacorilant's effectiveness. It was reported that the FDA expressed doubts related to the design of the GRACE study, which was critical to the drug's approval process. Despite this, Corcept’s public communications reportedly conveyed an overly positive outlook that did not reflect the actual risk assessments provided by the FDA.

What Investors Need to Know

Investors in Corcept Therapeutics who suffered losses during the specified timeframe have until April 21, 2026, to request appointment as the lead plaintiff in the class action. It's important to note that participation in the lawsuit does not necessitate serving in this capacity; all affected shareholders can benefit from potential recoveries. Levi & Korsinsky emphasizes that there are no out-of-pocket costs for investors to join the class action, ensuring accessibility for class members.

Joseph E. Levi, Esq., a spokesperson for the firm, encourages affected investors to come forward without concern for personal costs. Interested parties can initiate claims through a form provided by the firm or reach out directly via email or telephone.

Why Choose Levi & Korsinsky?

Over the past two decades, Levi & Korsinsky has established a robust track record within the field of securities litigation. The firm has successfully recovered hundreds of millions for disgruntled shareholders, offering extensive expertise in navigating complex securities cases. Its commitment to client advocacy is reflected in its ranking as one of the top securities litigation firms in the United States, recognized consecutively for seven years in ISS Securities Class Action Services’ Top 50 Report.

Levi & Korsinsky is strategically based in New York City, where its dedicated team of over 70 professionals is prepared to support shareholders throughout the legal process. The firm is committed to providing comprehensive representation to ensure investors are supported as they navigate potentially life-altering financial challenges.

Conclusion

As the class action progresses, impacted shareholders are encouraged to remain informed and proactive about their rights. The legal landscape surrounding securities fraud continues to evolve, and Levi & Korsinsky stands ready to combat injustices that investors may face. If you believe you qualify as a member of this class, consider reaching out to participate in the efforts to seek justice and recover losses incurred due to Corcept Therapeutics’ actions.

For further information regarding the filing and to ensure your rights are protected as a shareholder, contact Levi & Korsinsky directly, using the contact information provided. The time to act is now, before the April deadline approaches.